Smoking linked to lower Parkinson's risk through carbon monoxide

A recent international study published in *JAMA Neurology* suggests that exposure to carbon monoxide may help explain the lower incidence of Parkinson’s disease among smokers. Researchers followed 512,701 Chinese adults for 12 years, recording 1,131 cases of Parkinson’s and 2,949 other neurodegenerative conditions. Participants’ smoking habits were self‑reported and corroborated with breath carbon monoxide measurements, a standard biomarker of tobacco use.

The analysis found a significant inverse relationship between carbon monoxide levels and Parkinson’s risk, independent of other risk factors. While the study did not establish causality, the findings point to a potential neuroprotective effect of low‑level carbon monoxide exposure that could underlie the epidemiological observation that smokers are less likely to develop Parkinson’s disease. The researchers caution that smoking carries substantial health risks and that the protective signal is unlikely to justify tobacco use.

These results add a new dimension to the complex biology of Parkinson’s disease and highlight the need for further research into carbon monoxide’s role in neurodegeneration. Understanding the mechanisms behind this association could open avenues for novel therapeutic strategies that mimic the protective effect without the harms of smoking.